The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus

Published:2013-12-13 Issue:3 Volume:15 Page:311-324
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Ono Yuri,Nakamura Akinobu,Yong Cho Kyu,Nomoto Hiroshi

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/14656566.2014.868437

Reference28 articles.

1. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies

2. Diabetes Intervention Study: Multi-Intervention Trial in Newly Diagnosed NIDDM

3. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

4. Multicentre, Double-blind, Randomized Study of Mitiglinide Compared with Nateglinide in Type 2 Diabetes Mellitus Patients in China

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Japanese Clinical Practice Guideline for Diabetes 2019;Diabetology International;2020-07

2. Japanese Clinical Practice Guideline for Diabetes 2019;Journal of Diabetes Investigation;2020-07

3. Voglibose;Validamycin and its Derivatives;2017

4. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination;Expert Opinion on Pharmacotherapy;2014-07-21

5. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study;Expert Opinion on Pharmacotherapy;2014-05-27